InMed Pharmaceuticals Inc.

INM

CA4576376012

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-26 pm EDT			5-day change	1st Jan Change
0.23 ^USD	-8.73%		-20.72%	-44.71%

Apr. 18	InMed Pharmaceuticals Inc. Appoints David G. Morgan to its Scientific Advisory Board	CI
Apr. 04	InMed Pharmaceuticals Inc. Announces Additional Preclinical Data Demonstrating INM-901'S Positive Pharmacological Effects in the Potential Treatment of Alzheimer's Disease	CI

InMed Pharmaceuticals Inc. announced that it has received CAD 5.000002 million in funding

October 25, 2023

On October 26, 2023, InMed Pharmaceuticals Inc. closed the transaction.

Latest news about InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc. Appoints David G. Morgan to its Scientific Advisory Board	Apr. 17	CI
InMed Pharmaceuticals Inc. Announces Additional Preclinical Data Demonstrating INM-901'S Positive Pharmacological Effects in the Potential Treatment of Alzheimer's Disease	Apr. 04	CI
InMed Pharmaceuticals Inc. Provides Update on Pharmaceutical Development Programs	Feb. 13	CI
InMed Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 13	CI
InMed Pharmaceuticals Inc. Announces Chief Financial Officer Changes, Effective February 20, 2024	Feb. 09	CI
InMed Pharmaceuticals Inc. Announces Executive Changes, Effective February 20, 2024	Feb. 09	CI
Transcript : InMed Pharmaceuticals Inc. - Special Call	Jan. 25
Transcript : InMed Pharmaceuticals Inc. - Shareholder/Analyst Call	Dec. 19
Inmed Pharmaceuticals Inc. Announces the Launch of Inm-089	Nov. 29	CI
InMed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 14	CI
InMed Pharmaceuticals Inc. Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch 2023	Nov. 02	CI
InMed Pharmaceuticals Inc. announced that it has received CAD 5.000002 million in funding	23-10-25	CI
Inmed Pharmaceuticals Inc. Selects A Lead Alzheimer's Disease Drug Candidate, Named INM-901	23-10-24	CI
InMed Pharmaceuticals Inc. announced that it expects to receive CAD 5.000002 million in funding	23-10-23	CI
InMed Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-29	CI
InMed Pharmaceuticals Gets Non-Compliance Notice From Nasdaq	23-09-25	MT
Transcript : InMed Pharmaceuticals Inc. - Special Call	23-07-25
InMed Pharmaceuticals Inc. Announces Safety and Efficacy Results from its Phase 2 Clinical Trial, Called 755-201-EB	23-06-22	CI
InMed Pharmaceuticals Inc.'s Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting	23-06-01	CI
Transcript : InMed Pharmaceuticals Inc. - Special Call	23-05-31
InMed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-15	CI
InMed Pharmaceuticals Completes Patient Enrollment for Phase 2 Trial of INM-755 in Epidermolysis Bullosa	23-03-28	MT
InMed Pharmaceuticals Inc. Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating Inm-755 Cannabinol Cream for Epidermolysis Bullosa	23-03-28	CI
Top Premarket Gainers	23-03-20	MT
InMed Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-17	CI

Chart InMed Pharmaceuticals Inc.

Duration

Period

More charts

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing a pipeline of prescription-based products, including rare cannabinoids and cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs, as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its segments include InMed Pharmaceuticals and BayMedica. The InMed Pharmaceuticals segment is engaged in research and development of cannabinoid-based pharmaceutical products. The BayMedica segment is focused on developing manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 is used for the treatment of glaucoma.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
INMED PHARMACEUTICALS INC.	-44.71%	1.39M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs